Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

NCT05909826 is registered in ClinicalTrials.gov with Dong-A University Hospital as lead sponsor.

NCT NCT05909826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05909826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Dong-A University Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2023
Completion date
June 30, 2027
Enrollment
49 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse, multiple myeloma, refractory